Adagene Inc.
ADAGDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ADG126 Mono | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
ADG126 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Adagene Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Adagene Inc.'s (ADAG) pipeline across Phase 2. Its lead program is ADG126 Mono (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adagene Inc.'s next FDA catalyst?→
Adagene Inc.'s (ADAG) next tracked catalyst is a Phase 2 expected October 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADAG biotech catalysts?→
Add ADAG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adagene Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.